UNSPSC 51372303: Prodine

This classification denotes an opioid and analgesic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21J54X4Z4Z, chemically known as 1,3-dimethyl-4-phenyl-4-propionoxypiperidine but generally known as betaprodine, which bears US NIH Compound Identifier 6471. European Medicines Agency schedules Betaprodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05802MIG. The term BETAPRODINE is an International Non-Proprietary Name.

BETAPRODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1(C(CN(CC1)C)C)C1CCCCC1)C(=O)CC.

UNSPSC 51372303 Prodine is a Commodity code under which state and local governments procure naloxone and drug deactivation systems for public health and community emergency response. The work involves supplying pharmaceutical products and associated deactivation equipment to health departments, county agencies, and community health facilities, typically through annual supply agreements with quarterly or regular deliveries.

Seminole County, Florida has posted the primary recent opportunity under this code—an IFB (invitation for bid) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The solicitation (IFB60459723LAS) closed on July 26, 2023, and required vendors to submit electronic bids with all shipping and delivery costs included. The contract structure provides a two-year initial term with an optional one-year renewal, and vendors must comply with E-Verify, drug-free workplace certification, and federal compliance requirements including adherence to the Clean Air Act and Federal Water Pollution Control Act (potentially FEMA-funded). The procurement shows limited recent activity; the single posted opportunity in the source block is from Seminole County, Florida, suggesting that naloxone and deactivation-system procurement under this code remains concentrated in specific public health jurisdictions rather than dispersed across multiple states or issuing bodies.